Italy fines drug company for excessive pricing

Italy’s Competition Authority has fined Leadiant Biosciences €3.5 million for abusing its dominance by overcharging the national health service for an orphan drug, less than a year after the Dutch antitrust enforcer penalised the drugmaker for the same conduct.

Get unlimited access to all Global Competition Review content